Rockville, Maryland — According to state and local economic development sources TCR2 Therapeutics plans to build out 85,000 square feet of new space in Rockville. The company plans to occupy the new space in Rockville, on or about November 1, 2021. According to the company website At TCR Therapeutics, we are passionate about pioneering the T-cell receptor (TCR) complex to develop a pipeline of novel T cell therapies for patients suffering from solid tumors and hematological malignancies. As a clinical-stage immunotherapy company, TCR is transforming/leading the TCR cell therapy space by utilizing its proprietary TCR Fusion Construct T cells (TRuC-T cells) which specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). These unique characteristics enable TRuC-T cells to be a disruptive cellular therapy for patients suffering from a wide range of solid tumors and hematologic cancers. Our mission of building a leading a TRuC-T cell therapy company is based on innovation, an interdisciplinary team, patient-focus, and culture as strategy.

To learn more about TCR2 Therapeutics, visit http://www.tcr2.com/

Company Contact:
Garry Menzel, Chief Executive Officer
garry.menzel@tcr2.com
https://www.linkedin.com/in/gmenzel/
617-949-5200

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved